We are live on
!
Find out more
Arrowstreet Capital Portfolio holdings
AUM
$185B
1-Year Est. Return
39.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.23%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$43B
AUM Growth
+$121M
(+0.28%)
Cap. Flow
-$3.21B
Cap. Flow
% of AUM
-7.47%
Top 10 Holdings %
Top 10 Hldgs %
18.86%
Holding
2,029
New
505
Increased
717
Reduced
446
Closed
331
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$285M |
| 2 |
Applied Materials
AMAT
|
+$234M |
| 3 |
Micron Technology
MU
|
+$185M |
| 4 |
Merck
MRK
|
+$161M |
| 5 |
NXP Semiconductors
NXPI
|
+$152M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$505M |
| 2 |
Bank of America
BAC
|
+$339M |
| 3 |
Nike
NKE
|
+$335M |
| 4 |
Union Pacific
UNP
|
+$329M |
| 5 |
Citigroup
C
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.49% |
| 2 | Financials | 16.82% |
| 3 | Consumer Discretionary | 16.55% |
| 4 | Healthcare | 14.39% |
| 5 | Industrials | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
POLY
826
DELISTED
Plantronics, Inc.
POLY
| $5.54M | 0.01% |
+202,445
| New | +$6.09M |
|
827
Tandem Diabetes Care
TNDM
$1.58B
| $5.51M | 0.01% |
+92,500
| New | +$5.7M |
|
828
VeriSign
VRSN
$26.8B
| $5.51M | 0.01% |
28,600
-40,866
| -59% | -$7.68M |
|
829
Saia
SAIA
$9.5B
| $5.48M | 0.01% |
+58,869
| New | +$5.57M |
|
|
SHYF
830
DELISTED
The Shyft Group
SHYF
| $5.44M | 0.01% |
300,853
+208,976
| +227% | +$3.49M |
|
831
Amgen
AMGN
$224B
| $5.42M | 0.01% |
22,498
-667,339
| -97% | -$147M |
|
832
John B. Sanfilippo & Son
JBSS
$966M
| $5.42M | 0.01% |
59,380
+13,600
| +30% | +$1.32M |
|
833
NewMarket
NEU
$8.3B
| $5.4M | 0.01% |
11,092
+2,081
| +23% | +$1M |
|
834
Independent Bank Corp
IBCP
$832M
| $5.39M | 0.01% |
237,868
+43,719
| +23% | +$968K |
|
835
Vera Bradley
VRA
$97.5M
| $5.34M | 0.01% |
452,579
+71,141
| +19% | +$789K |
|
836
LG Display
LPL
$3.38B
| $5.3M | 0.01% |
763,881
-473,805
| -38% | -$2.95M |
|
837
Rayonier
RYN
$6.49B
| $5.3M | 0.01% |
178,239
-142,197
| -44% | -$3.87M |
|
838
Avient
AVNT
$4.17B
| $5.3M | 0.01% |
143,979
+78,979
| +122% | +$2.58M |
|
839
Hooker Furnishings Corp
HOFT
$161M
| $5.29M | 0.01% |
205,783
+121,326
| +144% | +$2.85M |
|
840
West Pharmaceutical
WST
$25.1B
| $5.28M | 0.01% |
35,135
-103,467
| -75% | -$15.1M |
|
841
Valley National Bancorp
VLY
$8.03B
| $5.27M | 0.01% |
+459,983
| New | +$5.29M |
|
842
Enel Chile
ENIC
$6.22B
| $5.26M | 0.01% |
1,107,933
+59,770
| +6% | +$258K |
|
|
RDUS
843
DELISTED
Radius Recycling
RDUS
| $5.26M | 0.01% |
242,539
-19,663
| -7% | -$419K |
|
|
PFC
844
DELISTED
Premier Financial Corp. Common Stock
PFC
| $5.25M | 0.01% |
166,561
+129,161
| +345% | +$3.89M |
|
845
Regis Corp
RGS
$71.1M
| $5.24M | 0.01% |
14,668
+1,966
| +15% | +$729K |
|
846
Okta
OKTA
$26.4B
| $5.21M | 0.01% |
+45,195
| New | +$5.2M |
|
847
JetBlue
JBLU
$2.17B
| $5.19M | 0.01% |
277,103
-22,853
| -8% | -$425K |
|
848
Lattice Semiconductor
LSCC
$18.5B
| $5.19M | 0.01% |
270,953
+250,753
| +1,241% | +$4.81M |
|
849
Digi International
DGII
$3.15B
| $5.18M | 0.01% |
292,528
+160,641
| +122% | +$2.55M |
|
850
Stellus Capital Investment Corp
SCM
$244M
| $5.17M | 0.01% |
363,545
+730
| +0.2% | +$10.2K |
|
Similar funds
VGA
Arrowstreet Capital's Q4 2019 Portfolio in Review
As of Q4 2019, Arrowstreet Capital held 2,029 positions worth $43B, up 0.28% from $42.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Arrowstreet Capital withdrew a net $3.21B in Q4 2019, closing 331 positions and reducing 446 holdings. Its most notable exit was Celgene Corp, an estimated $505M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Arrowstreet Capital opened a new position in Edwards Lifesciences worth $127M.
- Arrowstreet Capital's largest Q4 2019 buy was Edwards Lifesciences: 1,637,208 shares worth $127M.
- Arrowstreet Capital added most to Intel in Q4 2019, an estimated $285M increase.
- Arrowstreet Capital's biggest Q4 2019 reduction was Union Pacific, cutting an estimated $329M.
- Arrowstreet Capital fully exited Celgene Corp in Q4 2019, selling an estimated $505M.
- Arrowstreet Capital's ten largest holdings make up 19% of its $43B portfolio in Q4 2019.
- Arrowstreet Capital opened 505 new positions and closed 331 in Q4 2019.
- Arrowstreet Capital's portfolio value rose 0.28% quarter-over-quarter to $43B.
Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.